<DOC>
	<DOCNO>NCT00781287</DOCNO>
	<brief_summary>This investigator-initiated , two-year , randomize , control , single-center , open-label , pilot study compare 3-drug highly active antiretroviral therapy ( HAART ) 3-drug HAART plus raltegravir person acute early HIV-1 infection . The study test hypothesis use integrase inhibitor raltegravir ( 400 mg BID orally ) inhibit integration step HIV-1 life cycle conjunction HAART subject recently acquire HIV-1 infection decrease number HIV-1 infect CD4+ T-cells great extent 3-drug HAART regimen .</brief_summary>
	<brief_title>Raltegravir ( Isentress/MK-0518 ) HIV-1 Infected CD4 Cells During Acute/Early HIV-1</brief_title>
	<detailed_description>The study conduct UW Primary Infection Clinic UW AIDS Clinical Trials Unit . Secondary objective characterize safety , tolerability , plasma HIV-1 RNA CD4+ T-cell value . The 3-drug HAART chosen provide subject .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Acute Early HIV1 infection HIV1 RNA &gt; equal 500 copies/mL Acceptable safety lab result ( specify protocol ) Negative pregnancy test female Willingness use contraception ( female reproductive potential Prior receipt investigational HIV1 vaccine Use immunomodulators systemic steroid within 30 day entry Serious medical psychiatric illness would interfere study participation Active drug alcohol use would interfere study participation Allergy/hypersensitivity raltegravir Pre Postexposure prophylaxis exposure lead HIV1 acquisition Pregnancy breastfeed History malignancy ( localize squamous cell basal cell cancer skin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>human immunodeficiency virus</keyword>
	<keyword>raltegravir</keyword>
	<keyword>primary HIV infection</keyword>
	<keyword>HIV-1</keyword>
</DOC>